Subcutaneous vs Intravenous Administration of Medications and Fluids for Patients With Cancer in the US and Canada

Michael Tang; Mohamed Abdelaal; Jenny Lau; Alejandra Ruiz Buenrostro; Minxing Chen; Camilla Zimmermann; Eduardo Bruera

doi:10.1001/jamaoncol.2023.0239

Subcutaneous vs Intravenous Administration of Medications and Fluids for Patients With Cancer in the US and Canada

JAMA Oncol. 2023 May 1;9(5):717-719. doi: 10.1001/jamaoncol.2023.0239.

Authors

Michael Tang¹, Mohamed Abdelaal², Jenny Lau³, Alejandra Ruiz Buenrostro³, Minxing Chen⁴, Camilla Zimmermann³, Eduardo Bruera¹

Affiliations

¹ Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.
² The Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
³ Princess Margaret Cancer Centre, Department of Supportive Care, University Health Network, Toronto, Ontario, Canada.
⁴ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.

No abstract available

Plain language summary

This cross-sectional study compares rates of subcutaneous and intravenous administration of medications and fluids among patients with cancer in 2 acute palliative care units in the US and Canada.

MeSH terms

Administration, Intravenous
Canada
Humans
Infusions, Intravenous
Neoplasms* / drug therapy